Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01631227 | Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension | PHASE3 | COMPLETED | 665 | — | — | Jun 1, 2012 | Apr 1, 2013 | Jul 25, 2014 | 38 | Germany, Russia +1 |
Change from baseline of diastolic blood pressure (DBP), sitting
| Arm | Type | Description |
|---|---|---|
| Eprosartan | EXPERIMENTAL | Eprosartan + Placebo Eprosartan Mesylate |
| Eprosartan Mesylate | ACTIVE_COMPARATOR | Eprosartan Mesylate + Placebo Eprosartan |
| Name | Type | Description |
|---|---|---|
| Eprosartan | DRUG | Eprosartan 450 mg |
| Eprosartan Mesylate | DRUG | Eprosartan mesylate 600 mg |
| Placebo Eprosartan mesylate | DRUG | Placebo Eprosartan mesylate |
| Placebo Eprosartan | DRUG | Placebo Eprosartan |
Inclusion Criteria * Males or females with essential hypertension, blood pressure values between 140 mmHg and 179 mmHg systolic and between 90 mmHg and 109 mmHg diastolic * Given written informed consent prior to starting the study Exclusion Criteria * Women with childbearing potential, breast fe...